One-Liner
A mobile coaching and adherence app for Southeast Asian domestic workers and informal laborers using newly FDA-approved oral GLP-1 medication — killed by wealth filter: drug retail price far exceeds informal worker income with no third-party payer.
AI Thinking Process
FDA approved Foundayo (oral GLP-1) on 2026-04-01. SEA opportunity for informal workers with rising obesity rates and barrier to injectable distribution.
G019 wealth filter: SEA informal worker cannot afford $400–800/month US retail price for oral GLP-1. Hard wealth-filter fail.
Attempted to find third-party payer: (a) employer of domestic worker — misaligned incentive, (b) sending-country government program — does not exist for obesity drugs, (c) local insurer (Philhealth, BPJS) — no obesity drug coverage. All three payer pivots failed.
Wealth filter fails for direct consumer; no third-party payer with aligned incentives. Drug pricing barrier dominates — even with global tiered pricing, reaching $30/month for SEA informal workers is years away. Killed.
Kill Reason
Wealth filter fails at the individual consumer level. Oral GLP-1 (Foundayo/orforglipron) retail price in the US is expected at $400–800/month — months of income for a SEA informal worker. No third-party payer has aligned incentives: employers of domestic workers will not pay for weight-loss drugs, sending-country governments have no obesity drug coverage program, and statutory health insurance in Indonesia/Philippines/Vietnam does not cover obesity drugs. Drug pricing barrier is fundamental, not positional.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Wealth filter fails at the individual consumer level. Oral GLP-1 (Foundayo/orforglipron) retail price in the US is expected at $400–800/month — months of income for a SEA informal worker. No third-party payer has aligned incentives: employers of domestic workers will not pay for weight-loss drugs, sending-country governments have no obesity drug coverage program, and statutory health insurance in Indonesia/Philippines/Vietnam does not cover obesity drugs. Drug pricing barrier is fundamental, not positional.
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.